Categories
Videos

Winning the War Against Therapeutic Nihilism & Trusted Treatments vs Untested Novel Therapies – Dr. Peter McCullough, AAPS

Peter McCullough, MD, MPH speaks at the 78th Annual Meeting of AAPS on October 2, 2021.

Presentation notes:

  • 1min: Something was going very wrong very early in 2019.
  • 2m: The threshold for shutting down a new biologic product is just a few cases.
  • 3m: Covid-19 was going to be the showcase of what we could do for biotech.
  • 5m: The spike protein created by the new Covid-19 is a deadly protein.
  • 11m: Our institutions are all culpable in medical malfeasance.
  • 13m: We have the biggest biological catastrophe on our hands with a medicinal product in human history…and no-one knows how to stop it.
  • List of risk
  • 14m: 86% of deaths have no other explanation other than the vaccines.
  • 20m: We are in freefall into a lawless state. The Vaccines are not safe for use on either side of the Atlantic. It’s clear that this first generation of [Covid-19] vaccines is not safe.
  • 22m: The FDA did not approve Pfizer. The gave a continuation of the emergency use authorization and then conditionally approved Comirnaty with BioNTech which is legally and potentially medicinally distinct. The Pfizer approval is a false talking point.
  • 23m: When Pfizer came up for boosters, McCullough and his team presented at the FDA showing that death with the vaccine is greater than death just taking your chances with the infection. The vaccines aren’t safe across the board and the panel agreed 16:2 against the booster.
  • 26m: Data for the efficacy of the vaccines do not take into account the Delta variant. These vaccines have failed against Delta and other variants. Two-thirds who get sick with Delta are fully vaccinated. Data shows that the vaccines can’t stop transmission.
  • 27m: Effectiveness for Pfizer is at 42%. A vaccine that falls below 50% protection and can’t last a year is not a viable product. Pfizer has failed as a commercial product.
  • 29m: The CDC was telling us in May 2021 that the vaccines were failing. They started to do asymmetric reporting to craft a narrative that this was going to be a crisis of the unvaccinated but the CDC data showed the opposite. The ineptitude and willful misconduct of the people running our public health agencies is astounding.
  • 32m: The ‘99% of hospitalized were unvaccinated’ message was a propagandized false talking point because the data is not there.
  • 33m: The vaccines have had zero impact on the epidemic curve. Mortality is a function of treatment.
  • 34m: Many experts have been warning that we shouldn’t vaccinate into a pandemic because it creates resistance. As soon as we started vaccinating, the number of strains starting falling. The virus was figuring out how to thrive in the vaccinated.
  • 36m: The Delta variant has achieved antigenic escape. The data shows that the vaccinated is an equal threat to the unvaccinated.
  • 38m: Early home treatment is the only thing that makes sense. That’s what it should have always been.
  • 40m: Doctors at my institution cannot look me in the eye because they are so ashamed of what they’ve done during the course of this pandemic.
  • 44m: If you look through the clinical records [of those who have died] and I will tell you they were all inadequately treated.
  • 50m: Natural immunity is superior to vaccine immunity. If we vaccinate people who are covid-recovered, we harm them considerably. The only backstop is natural immunity.

File download:

A Guide to Home-Based COVID Treatment from the Association of American Physicians and Surgeons – PDF (1.4MiB)

Slides:

https://rumble.com/vnbv86-winning-the-war-against-therapeutic-nihilism-and-trusted-treatments-vs-unte.html

Backup mirrors:

Categories
Publications

COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study – Science Direct

First COVID-19 outpatient study based on risk stratification and early antiviral treatment at the beginning of the disease.

Low-dose hydroxychloroquine combined with zinc and azithromycin was an effective therapeutic approach against COVID-19.

Significantly reduced hospitalisation rates in the treatment group.

Reduced mortality rates in the treatment group.

https://web.archive.org/web/20201117161908/https://www.sciencedirect.com/science/article/pii/S0924857920304258

Categories
Publications

COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study – PubMed

The aim of this study was to describe the outcomes of patients with coronavirus disease 2019 (COVID-19) in the outpatient setting after early treatment with zinc, low-dose hydroxychloroquine and azithromycin (triple therapy) dependent on risk stratification. This was a retrospective case series study in the general practice setting. A total of 141 COVID-19 patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the year 2020 were included. The main outcome measures were risk-stratified treatment decision and rates of hospitalisation and all-cause death. A median of 4 days [interquartile range (IQR) 3-6 days; available for n = 66/141 patients] after the onset of symptoms, 141 patients (median age 58 years, IQR 40-67 years; 73.0% male) received a prescription for triple therapy for 5 days. Independent public reference data from 377 confirmed COVID-19 patients in the same community were used as untreated controls. Of 141 treated patients, 4 (2.8%) were hospitalised, which was significantly fewer (P < 0.001) compared with 58 (15.4%) of 377 untreated patients [odds ratio (OR) = 0.16, 95% confidence interval (CI) 0.06-0.5]. One patient (0.7%) in the treatment group died versus 13 patients (3.4%) in the untreated group (OR = 0.2, 95% CI 0.03-1.5; P = 0.12). No cardiac side effects were observed. Risk stratification-based treatment of COVID-19 outpatients as early as possible after symptom onset using triple therapy, including the combination of zinc with low-dose hydroxychloroquine, was associated with significantly fewer hospitalisations.

https://pubmed.ncbi.nlm.nih.gov/33122096/

Categories
Opinion

The Zelenko protocol – Dr. Eleftherios Gkioulekas, University of Texas Rio Grande Valley

A webpage curating content related to the early outpatient treatment protocol that has been proposed by Dr. Vladimir Zelenko for the SARS-CoV-2 virus. This web page is maintained by Eleftherios Gkioulekas, who is solely responsible for the content of this page. Eleftherios Gkioulekas has a Ph.D in Applied Mathematics from University of Washington in 2006. He is not a medical doctor and does not give medical advice. 

https://faculty.utrgv.edu/eleftherios.gkioulekas/zelenko/index.html

Categories
Publications

Doctors From Harvard and Yale Medical Schools Support Dr. Zelenko’s Treatment Method (The Zelenko Protocol)

JRC Publishing LLC, New Jersey has published an important book on treatment of COVID-19 virus. The book is based on medical research and treatment conducted by Dr. Roland DerwandProf. Martin Scholz and Dr. Zelenko.

The compendium presents treatment process and detailed experiences of COVID-19 patients while undergoing medical care with Dr. Zelenko and his colleagues from around the world. This extensive work, covering 248 pages, offers unparalleled breath of medical research and is the first volume to be published in this field to date. The e-book is available for download and is being distributed free of charge.

https://internetprotocol.co/covid-19/2020/07/21/yale-harvard-professors-support-zelenkos-protocol/

Categories
Publications

Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis

More than 1.6 million Americans have been infected with SARS-CoV-2 and >10 times that number carry antibodies to it. High-risk patients presenting with progressing symptomatic disease have only hospitalization treatment with its high mortality. An outpatient treatment that prevents hospitalization is desperately needed. Two candidate medications have been widely discussed: remdesivir, and hydroxychloroquine+azithromycin. Remdesivir has shown mild effectiveness in hospitalized inpatients, but no trials have been registered in outpatients. Hydroxychloroquine+azithromycin has been widely misrepresented in both clinical reports and public media, and outpatient trials results are not expected until September. Early outpatient illness is very different than later hospitalized florid disease and the treatments differ. Evidence about use of hydroxychloroquine alone, or of hydroxychloroquine+azithromycin in inpatients, is irrelevant concerning efficacy of the pair in early high-risk outpatient disease. Five studies, including two controlled clinical trials, have demonstrated significant major outpatient treatment efficacy. Hydroxychloroquine+azithromycin has been used as standard-of-care in more than 300,000 older adults with multicomorbidities, with estimated proportion diagnosed with cardiac arrhythmias attributable to the medications 47/100,000 users, of which estimated mortality is <20%, 9/100,000 users, compared to the 10,000 Americans now dying each week. These medications need to be widely available and promoted immediately for physicians to prescribe.

https://academic.oup.com/aje/advance-article/doi/10.1093/aje/kwaa093/5847586